吉非替尼治疗老年晚期非小细胞肺癌的临床观察  

The clinical observation of gefitinib in treating elderly advanced stage nsclc

作　　者：赵振华[1] 张杰[1] 侯梅[1] 李慧艳[1] 徐聂[1] 陈萍[1] 

机构地区：[1]四川大学华西医院,四川成都610041

出　　处：《西部医学》2012年第1期24-25,27,共3页Medical Journal of West China

摘　　要：目的观察吉非替尼治疗老年晚期非小细胞肺癌的疗效与毒副反应。方法选取26例经病理学诊断的老年晚期(Ⅲb期或Ⅳ期)非小细胞肺癌患者入组,单药口服吉非替尼250mg每日1次。评价其疗效及不良反应。结果26例患者中CR1例,PR8例,SD10例,PD7例;疾病控制率73.1%。随访4～36个月,中位随访17个月,中位生存期14.4个月(6.5～27.3个月),中位无进展生存11.5个月(5～16.5个月)。不良反应以皮疹、腹泻、转氨酶升高、恶心呕吐为主,多为轻度。结论吉非替尼治疗老年晚期非小细胞肺癌有较好的有效性和安全性。Objective To observe the curative and side effect of elderly advanced stage non-small cell lung cancer treating by gefitinib.Methods Analyzed 26 patients with advanced stage NSCLC（Ⅲb or Ⅳ）who were confirmed by pathology.All of them were orally administrated with gefinitib 250mg/d.observe the curative and side effect.Results All the 26 patients could be evaluated.1 cases CR;8 cases PR;10 cases SD and 7 cases PD.DCR73.1%.Life span was followed-up to 4——36 months,the middle followed-up time was 17 months.The middle survival time was 14.4 months（6.5-27.3months）.The middle time of no progression life span was 11.5 months（5-16.5months）.The most common drug related adverse events were rash,diarrhea,and hepatic dysfunction（GPT increase）,nausea and vomit,most of which were endurable.Conclusion Treating elderly advanced stage NSCLC with gefitinib seems to be safe and effective.

关 键 词：吉非替尼 非小细胞肺癌 老年 

分 类 号：R734.2[医药卫生—肿瘤]